Fi­bro­sis start­up touts mid-stage NASH tri­al as it moves sole can­di­date for­ward

A Pe­ter Thiel-backed biotech is re­port­ing a pos­i­tive tri­al in NASH — but it’s not plan­ning on work­ing there for the time be­ing.

Chemomab Ther­a­peu­tics, orig­i­nal­ly found­ed in Tel Aviv with em­ploy­ees based in both Is­rael and the US, an­nounced Tues­day morn­ing that its lead and on­ly pro­gram CM-101 met the pri­ma­ry safe­ty and tol­er­a­bil­i­ty end­point in a Phase IIa study. Sec­ondary end­points were al­so met, in­clud­ing lev­els of val­i­dat­ed liv­er fi­bro­sis bio­mark­ers mea­sured at base­line and at week 20.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER